1/22
05:08 pm
chrs
Coherus Oncology (NASDAQ:CHRS) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating on the stock.
High
Report
Coherus Oncology (NASDAQ:CHRS) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating on the stock.
1/16
08:00 am
chrs
Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape
Medium
Report
Functional Force: Precision Platforms Disrupt the 2026 Tumor Landscape
1/6
09:30 am
chrs
Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
Coherus Management to Present at the 44th Annual J.P. Morgan Healthcare Conference
1/6
08:27 am
chrs
SpyGlass Pharma Appoints Jean-Frédéric Viret as Chief Financial Officer [Yahoo! Finance]
High
Report
SpyGlass Pharma Appoints Jean-Frédéric Viret as Chief Financial Officer [Yahoo! Finance]
1/6
08:00 am
chrs
SpyGlass Pharma Appoints Jean-Frédéric Viret as Chief Financial Officer
Medium
Report
SpyGlass Pharma Appoints Jean-Frédéric Viret as Chief Financial Officer
1/5
09:30 am
chrs
Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)
Medium
Report
Coherus Oncology Announces Publication in Molecular Cancer Therapeutics Highlighting the Strong Pharmacology of Investigational CCR8 Antibody Tagmokitug (CHS-114)
12/8
08:30 am
chrs
Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma
Low
Report
Coherus Announces Six-Year JUPITER-02 Follow-up Results Showing LOQTORZI® plus Chemotherapy Nearly Doubles Median Overall Survival in Nasopharyngeal Carcinoma
11/7
09:00 am
chrs
Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody
Low
Report
Coherus Oncology Presents at SITC Clinical Multiomic Biomarker Data for CHS-114, a Highly Selective anti-CCR8 Cytolytic Antibody
11/6
04:14 pm
chrs
Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update
Medium
Report
Coherus Oncology Reports Third Quarter 2025 Financial Results and Provides Business Update
11/6
01:54 pm
chrs
Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer
Low
Report
Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer